🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Sam Bankman-Fried’s Legal Team Demands ADHD Medication in Filing

Published 16/10/2023, 14:22
Sam Bankman-Fried’s Legal Team Demands ADHD Medication in Filing

Coin Edition -

  • Sam Bankman-Fried’s legal team is demanding the FTX founder’s access to ADHD medication.
  • Mark Cohen noted that the lack of Adderall can affect Bankman-Fried’s testimony.
  • While Judge Kaplan revoked Bankman-Fried’s bail in August, he allowed treatment for ADHD and depression.

The legal team defending FTX founder Sam Bankman-Fried is negotiating to access his ADHD medication, Adderall. As Bankman-Fried’s criminal trial in a New York court rolls into its third week, legal representative Mark Cohen expressed that the challenge of ensuring his client receives a sufficient quantity of Adderall is impeding the defense team’s capacity to fight their case.

In a court filing from Sunday, October 15, Cohen highlighted that the lack of attention deficit hyperactivity disorder (ADHD) medication may have a significant impact on whether Bankman-Fried can “meaningfully participate” in the trial. Furthermore, he penned, “Mr. Bankman-Fried has been doing his best to remain focused during the trial for the past two weeks.”

As per earlier court documents, Bankman-Fried has been consuming Adderall tablets three to four times daily over the past three years. His legal team has asserted that this medication is indispensable for SBF. Moreover, during interactions with potential jurors, his attorneys called out any potential biases related to Bankman-Fried’s body language, which might be influenced by his ADHD.

Back in August, U.S. District Judge Lewis Kaplan revoked Bankman-Fried’s bail. However, Kaplan ruled in favor of Bankman-Fried receiving treatment for ADHD and depression. This occurred following Bankman-Fried sharing confidential writings from the prosecution’s key witness, Caroline Ellison, the former CEO of Alameda Research.

In the latest updates from Bankman-Fried’s trial, Ellison detailed how Bankman-Fried orchestrated “billions of dollars” in customer funds to support high-risk investments, ultimately resulting in the collapse of FTX.

On October 14, Bloomberg reported that Sam Bankman-Fried’s statements in tweets and group chats were being used as evidence against him. Additionally, prosecutors have introduced snapshots of messages, social media posts, and internal records to identify disparities between his public announcements and confidential instructions to his inner circle.

The post Sam Bankman-Fried’s Legal Team Demands ADHD Medication in Filing appeared first on Coin Edition.

Read more on Coin Edition

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.